迈威生物股价跌5.01%，申万菱信基金旗下1只基金重仓，持有28.85万股浮亏损失58.28万元

Group 1 - The core point of the news is that Maiwei Biotech's stock has experienced a decline of 5.01%, with a current price of 38.28 CNY per share and a total market capitalization of 15.297 billion CNY [1] - Maiwei Biotech, established on May 12, 2017, specializes in the research, production, and sales of therapeutic biological products, with 99.91% of its revenue coming from product sales [1] - The trading volume for Maiwei Biotech reached 288 million CNY, with a turnover rate of 3.63% [1] Group 2 - According to data, the Shenyuan Lingxin Fund holds a significant position in Maiwei Biotech, with the Shenyuan Lingxin Medical Pioneer Stock A fund (005433) owning 288,500 shares, representing 4.98% of the fund's net value [2] - The Shenyuan Lingxin Medical Pioneer Stock A fund has reported a floating loss of approximately 582,800 CNY today [2] - The fund has a total asset size of 1.05 billion CNY and has experienced a year-to-date return of 6.17%, ranking 2698 out of 5579 in its category [2]